News for ChromaDex Corporation (CDXC)

Published at

Jul 23, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

Jul 14, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

Jun 20, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

Jun 9, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

Jun 4, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

May 22, 2025 7:00 PM

by seekingalpha.com

positive

positive

Niagen Bioscience: Overbought After Rally (NASDAQ:NAGE)

Niagen Bioscience posts strong Q1 2025 growth and raises guidance. Click here for a full investment analysis.

CDXC

Read more →
Published at

May 5, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

\n[url=\

ERII CLAR CDXC

Read more →
Published at

Apr 29, 2025 4:00 PM

by gurufocus.com

mixed

mixed

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC CWBR

Read more →
Published at

Apr 28, 2025 4:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

Mar 20, 2025 3:00 PM

by gurufocus.com

positive

positive

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

CDXC

Read more →
Published at

Mar 13, 2025 3:00 PM

by gurufocus.com

positive

positive

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

[url="]ChromaDex Corp.[/url] (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, toda

CDXC

Read more →
Published at

Mar 6, 2025 4:30 PM

by seekingalpha.com

positive

positive

ChromaDex Stock Capitalizes On Longevity Boom But Valuation Remains High (NASDAQ:CDXC)

ChromaDex reports 37.41% revenue growth with Niagen leading success, despite risks, its e-commerce surge and profits signal potential. Read more here.

CDXC

Read more →
Published at

Mar 5, 2025 2:13 PM

by insidermonkey.com

positive

positive

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's Fourth Quarter of 2024 Earnings Conference Call.

CDXC

Read more →
Published at

Mar 5, 2025 2:54 AM

by seekingalpha.com

neutral

neutral

ChromaDex Corporation 2024 Q4 - Results - Earnings Call Presentation (NASDAQ:CDXC)

The following slide deck was published by ChromaDex Corporation in conjunction with their 2024 Q4 earnings call.

CDXC

Read more →
Published at

Mar 5, 2025 2:53 AM

by seekingalpha.com

neutral

neutral

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ETCompany ParticipantsBen Shamsian - Vice President, Lytham...

CDXC

Read more →
Published at

Mar 4, 2025 11:15 PM

by zacks.com

neutral

neutral

ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 50% and 7.47%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

CDXC

Read more →
Published at

Mar 4, 2025 11:00 PM

by gurufocus.com

positive

positive

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, w

CDXC

Read more →
Published at

Feb 25, 2025 11:00 PM

by gurufocus.com

positive

positive

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

[url="]ChromaDex Corp. [/url](NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces

CDXC

Read more →
Published at

Dec 26, 2024 3:48 PM

by zacks.com

neutral

neutral

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.

TARS STOK CDXC ADMA

Read more →
Published at

Dec 9, 2024 2:50 PM

by zacks.com

neutral

neutral

ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

CDXC

Read more →